Health Care·Life Sciences Tools & Services·$174.6B
Thermo Fisher Scientific (TMO) operates in the health care sector, specializing in life sciences tools and services. The company plays a crucial role in providing essential products and services that support research, diagnostics, and manufacturing in the life sciences field.
Earnings Per Share (EPS)
EPS is a key indicator of profitability and will help assess how well the company is managing costs and generating income.
Revenue Growth
Revenue growth is vital to understanding the company's market demand and overall business health, especially in the competitive life sciences sector.
1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
8Q
EPS Beat Rate
100%
Avg EPS Surprise
+3.04%
Avg Stock Reaction
+0.93%
In Q1 2026, Thermo Fisher reported an EPS of $5.44, exceeding expectations by 4.68%. However, the stock declined by 9.20% the following day, indicating potential market concerns despite the earnings beat.
Management Promises & Guidance
Overall expectations for Thermo Fisher's upcoming earnings are cautious, given the recent stock performance despite previous earnings beats. Investors are looking for signs of sustained growth and profitability.
Bull Case
The optimistic view hinges on continued strong demand for life sciences tools and services, which could lead to significant revenue growth and improved margins.
Bear Case
On the other hand, if the company shows signs of slowing growth or rising costs, it could raise concerns about its ability to maintain profitability, leading to further stock declines.
Earnings Per Share (EPS)
N/AEPS is a key indicator of profitability and will help assess how well the company is managing costs and generating income.
Revenue Growth
N/ARevenue growth is vital to understanding the company's market demand and overall business health, especially in the competitive life sciences sector.
Gross Margin
N/AGross margin reflects the efficiency of production and pricing strategies, which are critical in maintaining profitability.
The print will turn on these two things.
Q1
What is the revenue growth rate compared to last year?
Revenue growth is critical to assess the company's market position and demand for its products, especially in a competitive environment.
Q2
How is the gross margin trending this quarter?
Understanding gross margin trends will provide insight into the company's cost management and pricing strategies, which are essential for profitability.
Why consensus could be wrong
The consensus may underestimate the potential for robust revenue growth driven by increased demand in the life sciences sector, particularly in diagnostics and research.
Supporting Evidence
The company has consistently beaten EPS estimates, indicating strong operational performance.
Recent trends in the health care sector suggest increased investment in life sciences tools, which could benefit Thermo Fisher.
Options pricing reflects uncertainty, suggesting that the market may not fully appreciate the company's growth potential.
Key Risk
If revenue growth exceeds 10%, it could challenge the current bearish sentiment and shift investor expectations.
Pre-commit to what would confirm each case.
The core thesis this quarter revolves around the balance between revenue growth and cost management, which will significantly impact investor sentiment.
Bull Confirmed If
Revenue growth of 10% or more year-over-year would confirm a strong demand for Thermo Fisher's products.
Bear Confirmed If
If gross margins fall below 50%, it could indicate rising costs that threaten profitability.
Implied Move
±4.2%
The options market is pricing in a potential move of 4.2% around the earnings announcement, reflecting uncertainty about the results.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Thermo Fisher beats expectations and raises guidance, history suggests the stock could rise by around 0.93% on the following day, confirming strong demand.
In-Line / Cautious
An in-line report with cautious commentary may lead to muted stock movement, as investors weigh the implications of the results.
Miss
If the company misses expectations, history suggests a potential decline of around 4.48%, reflecting investor disappointment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MEDPACE HLDGS INC
Jul 20, 2026